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BACKGROUND: Oxaliplatin and 5-fluorouracil (5-FU) currently form the backbone of conservative treatment in patients with metastatic
colorectal cancer. Tumour responses to these agents are highly variable, but the underlying mechanisms are poorly understood. Our
previous results have indicated that oncogenic KRAS in colorectal tumour cells sensitises these cells to chemotherapy.
METHODS: FACS analysis was used to determine cell-cycle distribution and the percentage of apoptotic and mitotic cells.
A multiplexed RT–PCR assay was used to identify KRAS-controlled apoptosis regulators after exposure to 5-FU or oxaliplatin.
Lentiviral expression of short-hairpin RNAs was used to suppress p53 or Noxa.
RESULTS: Oncogenic KRAS sensitised colorectal tumour cells to oxaliplatin and 5-FU in a p53-dependent manner and promoted p53
phosphorylation at Ser37 and Ser392, without affecting p53 stabilisation, p21 induction, or cell-cycle arrest. Chemotherapy-induced
expression of the p53 target gene Noxa was selectively enhanced by oncogenic KRAS. Suppression of Noxa did not affect p21
induction or cell-cycle arrest, but reduced KRAS/p53-dependent apoptosis after exposure to chemotherapy in vitro and in tumour
xenografts. Noxa suppression did not affect tumour growth per se, but strongly reduced the response of these tumours to
chemotherapy.
CONCLUSION: Oncogenic KRAS determines the cellular response to p53 activation by oxaliplatin or 5-FU, by facilitating apoptosis
induction through Noxa.
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Chemotherapy of colorectal cancer mainly involves the fluoro-
pyrimidine drug 5-fluorouracil (5-FU) and the platinum drug
oxaliplatin (Chau and Cunningham, 2009). The response of
colorectal tumours to these compounds is determined both by
the genetic background of tumour cells as well as by environ-
mental cues. Colorectal tumours frequently harbour activating
mutations in the KRAS proto-oncogene, which drives tumour
progression (Andreyev et al, 1998, 2001). Signalling by constitu-
tively active Ras proteins can either promote or prevent the
induction of apoptosis, depending on the cellular context and on
the specific isoform studied (Vos et al, 2000; Khokhlatchev et al,
2002). For instance, the expression of oncogenic N-Ras but not
that of oncogenic K-Ras in the colonic epithelium provides
protection against enterocyte apoptosis in a colitis model (Haigis
et al, 2008). In contrast, we along with others have previously
shown that oncogenic KRAS promotes apoptosis of human
colorectal tumour cells exposed to either 5-FU or oxaliplatin
(Klampfer et al, 2005; Smakman et al, 2006). Although activating
mutations in KRAS alone do not reliably predict the response of
colorectal tumours to chemotherapy (Loriot et al, 2009), these
findings do suggest that the acquisition of KRAS mutations may be
associated with an increased propensity to undergo apoptosis.
Interestingly, several studies have connected Ras signalling to the
activation of p53 (Ries et al, 2000; Lin and Lowe, 2001; Ferbeyre
et al, 2002). In non-transformed cells, the activation of p53 by
oncogenic Ras induces a permanent cell-cycle exit and induction
of cellular senescence (Serrano et al, 1997; Bardeesy and Sharpless,
2006; Ruiz et al, 2008). However, p53 activation in (colorectal)
tumour cells does not lead to senescence, but rather leads to
apoptosis or cell-cycle arrest (Aneja et al, 2007; Toscano et al,
2007; Braun et al, 2008). The tumour suppressor protein p53 is a
key player in determining the response of colorectal tumour cells
to oncogenic stress and chemotherapy by oxaliplatin and 5-FU
(Vousden and Lu, 2002; Adamsen et al, 2007; Borralho et al, 2007;
Toscano et al, 2007). The determinants specifying p53 signalling
output are the subject of intense investigation. Although
p53-induced activation of the CDK inhibitor p21 is sufficient to
cause cell-cycle arrest in most cell types, p53-induced apoptosis is
more complex and involves the activation of different sets of target
genes in different tissues and in response to different stimuli
(Oren, 2003; Yu and Zhang, 2005; Kuribayashi and El-Deiry, 2008;
Vousden and Prives, 2009). In colorectal tumour cells, the p53-
upregulated modulator of apoptosis (PUMA) has an important role in
the induction of apoptosis exposed to 5-FU or oxaliplatin (Wang et al,
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s2007). The p53-upregulated modulator of apoptosis belongs to the
family of ‘BH3-only’ proteins that promote apoptosis by neutralis-
ing Bcl-2 family pro-survival proteins, including Bcl-2, Bcl-xL, and
myeloid cell leukaemia sequence 1 (Mcl-1) (Willis and Adams,
2005; Shibue and Taniguchi, 2006). p53 also promotes the
expression of Noxa, another BH3-only family member (Oda
et al, 2000). The p53-upregulated modulator of apoptosis is
generally considered to be a more potent apoptosis inducer than
Noxa, because it can neutralise multiple Bcl-2 family members,
whereas Noxa selectively neutralises Mcl-1 (Willis and Adams,
2005; Shibue and Taniguchi, 2006; Ploner et al, 2008). However,
Noxa-dependent cell death may be particularly important in
malignant cells (Suzuki et al, 2009), and Noxa could therefore
represent a potential therapeutic target.
In this report, we studied the contribution of p53 and p53 target
genes to KRAS-induced sensitisation of colorectal tumour cells to
5-FU and oxaliplatin. We found that the mutant KRAS cooperates
with p53 in the induction of Noxa, but not other pro-apoptotic p53
target genes. Furthermore, we show that Noxa does not control
tumour growth per se, but is an important determinant of the
tumour response to chemotherapy.
MATERIALS AND METHODS
Cell culture
The human colorectal cancer cell line HCT116
G13D/wt and the isogenic
cell line Hkh2
ko/wt lacking the KRAS
D13 allele were kindly provided by
Shirasawa et al (1993). HCT116 p53KO cells were kindly provided by
Dr Vogelstein. All cells were cultured in Dulbecco’s modified Eagle’s
medium (Dulbecco, ICN Pharmaceuticals, Costa Mesa, CA, USA)
supplemented with 5% (v/v) fetal calf serum, 2mM glutamine,
0.1mgml
 1 streptomycin, and 100Uml
 1 penicillin. All cells were
kept at 371C in a humidified atmosphere containing 5% CO2.
Oxaliplatin was obtained from Sanofi Aventis (Gouda, The
Netherlands) and 5-FU was from TEVA (Haarlett, The Netherlands).
Antibodies
The following antibodies were obtained from Cell Signaling
Technology Inc. (Danvers, MA, USA): anti-Puma (no. 4976),
anti-caspase-8 1C12 (no. 9746), anti-cleaved caspase-3 ASP175 (no.
9661), and the secondary antibody peroxidase-conjugated anti-
rabbit IgG. The following antibodies were all obtained from Santa
Cruz Biotechnology (Heidelberg, Germany): anti-p53 DO-1
(sc-126) and anti-p21 C19 (sc-397). Anti-Noxa (IMG-349A) was
purchased from Imgenex Corporation (San Diego, CA, USA); anti-a
tubulin from Sigma Aldrich (St Louis, MO, USA); anti-b-actin
AC-15 (NB600-501) from Novus Biologicals LLC (Littleton, CA,
USA); secondary antibody peroxidase-conjugated anti-mouse IgG
from Dako (Glostrup, Denmark); anti-phospho-histone H3 (Ser10)
(06-570) from Millipore (Billerica, MA, USA); and the secondary
antibody Cy5 AffiniPure F(ab0)2 Frag Donkey anti-rabbit IgG from
Jackson Immunoresearch Europe (Suffolk, UK). For immunohis-
tochemical staining, anti-Ki-67 clone SP-6 (no. RM-9106S) was
acquired from Lab Vision Products Thermo Fisher Scientific
(Chesire, UK) and anti-cleaved caspase-3 (no. 559565) from BD
Pharmingen (Franklin Lakes, NJ, USA) was used.
Lentiviral constructs and transduction
The lentiviral short-hairpin RNA (shRNA) construct targeting p53
was kindly provided by Dr AG Jochemsen. Noxa-targeting
lentiviral constructs were obtained from the TRC-Mm1.0 library
(Sigma Aldrich). The target set used for Noxa (NM_021127)
included TRCN0000150555, TRCN0000155978, TRCN0000151311,
TRCN0000153637, and TRCN0000155570. Of these constructs,
subsequent transduction of cells with TRCN0000151311, followed
by transduction with TRCN0000153637 produced the best knock
down. As the control vector, we used the same vector containing a
sequence targeting luciferase, TGACCAGGCATTCACAGAAAT.
For virus production, we used the third-generation packaging
system, kindly provided by Professor D Trono.
p53 phosphorylation status
The phosphorylation status of p53 was analysed using the phospho-
p53 antibody sampler kit no. 9919 (Cell Signaling Technology Inc.).
FACS analysis
Cells were fixed in 70% ice-cold ethanol and incubated for 2h at 41C.
To determine the percentage of mitosis, cells were washed in PBS-
Tween (0.1%) and incubated with anti-phospho-histone H3 antibody
for 1h at RT, after which cells were incubated with CY5-labelled
secondary antibody for 1h at RT. To assess the cell-cycle profile,
fixed cells were treated with RNAse and DNA was stained with
propidium iodide (PI). All samples were analysed by bivariate flow
cytometry using Cell Quest and Modfit software (Becton Dickinson,
Breda, The Netherlands).
MLPA
The MLPA was performed according to the manufacturer’s
protocol (MRC-Holland BV, Amsterdam, The Netherlands).
RT–PCR
The RT–PCR was performed by isolating RNA using Trizol, and
conversion to cDNA using Superscript2 (Invitrogen, Breda, The
Netherlands). The primers used were for Noxa forward: 50-G
GTACCCTGGGAAGAAGGCGCG-30 and reverse: 50-GAATTCT
CAGGTTCCTGCGCAGAAG-30. L32 served as a loading control
with the forward primer: 50-GCCCAAGATCGTCAAAAAGA-30, and
reverse 50-ATTGTGGACCAGGAACTTGC-30.
Immunofluorescence
Immunofluoresence was performed as described in the study by
Lindqvist et al (2007). Images were acquired on a Zeiss LSM510
META microscope (Zeiss, Sliedrecht, The Netherlands). MitoTracker
(Invitrogen) was used according to the manufacturer’s protocol.
Tumour model and chemotherapy
All experiments were conducted in accordance with the guidelines
of the Animal Welfare Committee of the University Medical Center
Utrecht, The Netherlands. Male Balb/C Nu/Nu mice (10–12 weeks)
were purchased from Charles River (Sulzfeld, Germany) and were
housed in filter top cages. Tumour cells were injected subcuta-
neously (10
6 cells in 100ml 1/3 diluted Matrigel (Becton
Dickinson)). When tumours reached B100mm
3, mice were
treated with 12.5mgkg
 1 oxaliplatin or vehicle intraperitoneally
(day 0). A second dose of oxaliplatin (12.5mgkg
 1) was
administered on day 7. Tumour growth was assessed every
2 days, and mice were terminated 14 days after the start of
treatment. The volume (V) was calculated by V¼A B
2 0.5236
(A¼largest diameter, B¼diameter perpendicular to A).
RESULTS
KRAS
D13 sensitises tumour cells to chemotherapy-induced
apoptosis without overriding cell-cycle arrest
Oncogenic KRAS may sensitise tumour cells to apoptosis
induction by forcing cell-cycle progression in the presence of
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sDNA damage. Therefore, we analysed whether KRAS-facilitated
apoptosis induction by 5-FU and oxaliplatin was accompanied
by escape from cell-cycle arrest. HCT116 (KRAS
wt/D13) and
isogenic Hkh2 cells (KRAS
wt/ko) were treated with oxaliplatin
and 5-FU for three consecutive days. Apoptosis induction and
cell-cycle distribution were then measured by FACS analysis of
PI-stained cells. In addition, mitotic progression was measured
by FACS analysis of phospho-histone H3-positive cells.
We found that KRAS greatly facilitated apoptosis induction
by both chemotherapeutics as described previously (Klampfer
et al, 2005; Smakman et al, 2006) (Figure 1A and B). HCT116
cells underwent a bona fide cell-cycle arrest and did not
enter mitosis before apoptosis induction (Figure 1C). This
suggests that KRAS does not promote chemotherapy-
induced apoptosis by forcing mitotic entry in the presence of
DNA damage.
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Figure 1 KRAS
D13 sensitises tumour cells to chemotherapy-induced apoptosis without overriding cell-cycle arrest. (A) HCT116 and Hkh2 cells were
treated with 8mgml
 1 oxaliplatin or 8mgml
 1 5-FU for three consecutive days. Cells were then fixed in formalin and stained with propidium iodide (PI). The
sub-G1 fraction was determined by FACS analysis. Error bars represent s.e.m. based on three independent experiments (*Po0.05). (B) Cells were treated
as described in panel A. After 2 days, cells were fixed and the cycle profiles of PI-stained cells were analysed by FACS. (C) Cells were treated as described in
panel A and fixed at the indicated time points. Mitotic cells were then stained using anti-phospho-histone H3 and analysed by FACS. Error bars represent
s.e.m., based on three independent experiments (*Po0.001).
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sKRAS
D13 promotes apoptosis without affecting p53
stabilisation or p21 induction
Next, we tested whether the KRAS status would influence p53
stabilisation. We found that p53 was stabilised to a similar extent
in both HCT116 and Hkh2 cells in response to either oxaliplatin or
5-FU (Figure 2A). Nuclear accumulation of p53 was also similar in
both cell types (Figure 2B). We were unable to detect p53
localisation to the mitochondria in oxaliplatin- or 5-FU-treated
HCT116 or Hkh2 cells (Supplementary Figure 1). However,
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Figure 2 Oncogenic KRAS promotes apoptosis without affecting p53 stabilisation or p21 induction. (A) HCT116 and Hkh2 cells were treated with
oxaliplatin (8mgml
 1)o r5 - F U( 8mgml
 1) for 0–3 days as indicated. Lysates were prepared and analysed for the presence of p53, p21, cleaved caspase-8, tubulin,
and actin by western blotting. (B) HCT116 and Hkh2 cells were treated for 24h with oxaliplatin or 5-FU. Cells were then processed for immunofluorescence
analysis of p53 localisation. Bars represent 50mm. (C) Cells were treated as described in panel B and cell lysates were analysed for the presence of p53 (total p53)
and p53 phosphorylated at residues Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392. The signals for Ser6, Ser9, Ser20, and Ser46 were below the detection limit.
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swhereas p53 stabilisation correlated caspase-8 cleavage in HCT116
cells, this was not observed in Hkh2 cells (Figure 2A). Induction of
the cyclin-dependent kinase inhibitor and p53 target p21 by
chemotherapy was not affected by KRAS status (Figure 2A), which
is in line with the finding that both apoptosis-prone and apoptosis-
resistant cells undergo cell-cycle arrest.
KRAS promotes p53 phosphorylation of p53 on Ser37 and
Ser392
The differential regulation of p53 target genes is controlled by
both post-translational modification and its binding partners.
In this study, we tested whether KRAS status modified
chemotherapy-induced phosphorylation of p53. We found that
oxaliplatin- or 5-FU-induced p53 phosphorylation on Ser15 was
not altered, but phosphorylation on Ser37 and Ser392 was far more
pronounced in cells expressing oncogenic KRAS (Figure 2C).
Again, p53 stabilisation was not different between HCT116 and
Hkh2 cells (Figure 2C).
p53 is required for KRAS
D13-stimulated tumour cell
sensitisation to apoptosis
Next, we tested whether p53 was required for the sensitising effect
of KRAS
D13 on chemotherapy-induced tumour cell apoptosis. To
this end, we created stable p53 knockdown cell lines by using
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Figure 3 Wild-type p53 is required for sensitisation to apoptosis by oncogenic KRAS. (A) HCT116 and Hkh2 cells were transduced with a lentiviral
control shRNA vector, and with a vector targeting p53. All four cell lines were then treated for 0–3 days with oxaliplatin (8mgml
 1)o r5 - F U( 8mgml
 1). After fixation,
cells were stained with propidium iodide and the sub-G1 fraction was determined by FACS analysis. Error bars represent s.e.m. of three independent experiments
(*Po0.05). (B) Cells were treated as described in panel A, and cell lysates were prepared and analysed for the presence of p53 and p21 by western blotting.
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Figure 4 Oncogenic KRAS is required for p53-dependent induction of Noxa by chemotherapy. (A) HCT116 and Hkh2 cells were treated with
oxaliplatin (8mgml
 1) or 5-FU (8mgml
 1) for 24h. Total RNA was then isolated and tested for the presence of Noxa and L32 mRNA by RT–PCR. (B)
Cells were treated for 0–3 days with oxaliplatin or 5-FU, and Noxa protein levels were determined by western blot analysis. (C) HCT116 expressing
(HCT116 p53WT) or lacking p53 (HCT116 p53KO) were cultured in the presence of oxaliplatin or 5-FU for 0–3 days as indicated. Lysates were prepared
and analysed for the presence of p53, p21, PUMA, and Noxa protein levels. (D) The experiment described in panel C was repeated three times and all
Noxa blots were scanned densitometrically to quantify the induction. Graphs represent % induction relative to day 0. *Indicates statistically significant
differences (Po0.05).
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slentiviral RNA interference. Knockdown of p53 in HCT116 cells
strongly reduced apoptosis in response to oxaliplatin or 5-FU in
HCT116 cells (Figure 3A, upper panel). However, p53 knockdown
did not affect 5-FU- or oxaliplatin-induced apoptosis in Hkh2 cells
(Figure 3A, lower panel). In both cell types, p21 induction was
completely abrogated (Figure 3B). These results show that the
apoptosis-promoting effect of KRAS
D13 depends on the presence of
wild-type p53.
5-FU and oxaliplatin induction of Noxa requires oncogenic
KRAS and wild-type p53
To gain further insight into the mechanism by which oncogenic
KRAS facilitates apoptosis induction in response to chemotherapy,
we performed a multiplexed RT–PCR analysis (MLPA) for the
induction of apoptosis control genes by either 5-FU or oxaliplatin
in HCT116 and Hkh2 cells (Supplementary Figure 2A). Of the 32
genes tested in this screen, only Noxa (PMAIP1) was selectively
induced in HCT116 cells. The Noxa-related PUMA gene was
induced to a similar extent in HCT116 and Hkh2 cells by 5-FU or
oxaliplatin. However, chemotherapy induction of PUMA mRNA
levels was relatively low. The PUMA/Noxa binding partner Mcl-1
was not induced by either drug (Supplementary Figure 2B). Both
RT–PCR and western blot analysis confirmed the selective
induction of Noxa in HCT116 cells, but not in Hkh2 cells
(Figure 4A and B) and the relatively poor induction of PUMA
(Figure 4B). Thus, induction of the p53 target gene Noxa by 5-FU
and oxaliplatin requires the presence of oncogenic KRAS. Next, we
tested the dependency of Noxa induction on p53 in HCT116 cells.
As expected, the induction of Noxa by oxaliplatin or 5-FU was
strongly reduced in cells lacking p53 (Figure 4C). Quantification of
Noxa induction in response to chemotherapy by densitometric
scanning of the blots of three independent experiments showed
that Noxa induction requires the presence of both wild-type p53
and oncogenic KRAS (Figure 4D).
A critical role for Noxa in apoptosis induction by
oxaliplatin and 5-FU
We next tested whether KRAS-dependent induction of Noxa was
instrumental in sensitising HCT116 cells to oxaliplatin and 5-FU.
To this end, we created stable cell lines in which Noxa was
suppressed by RNA interference. Of a set of five Noxa-targeting
shRNA constructs, two (nos 2 and 3) reduced Noxa protein levels
to B30% of control levels. Combination of these targeting
constructs further reduced Noxa levels to B10% of control levels
(Figure 5A). Exposure of control cells and Noxa-suppressed cells to
either oxaliplatin or 5-FU showed that Noxa suppression protected
HCT116 cells from apoptosis induction by 50–70% over a period
of 3 days. In contrast, the relatively inefficient targeting construct
no. 1 (20–30% knockdown) had only a marginal protective effect
(Figure 5A and B), when compared with control cells expressing
luciferase-targeting shRNA.
Therapeutic efficacy of oxaliplatin and induction of
tumour cell apoptosis requires Noxa
We next tested whether suppression of Noxa affected tumour
growth and therapy resistance. To this end, control HCT116 cells
(luc-shRNA) and Noxa-suppressed HCT116 cells were injected
into the flanks of nude mice and tumour growth was followed over
time. When tumours reached a size of 100mm
3, PBS or oxaliplatin
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Figure 5 Contribution of Noxa to KRAS-facilitated apoptosis induction in response to chemotherapy. (A) HCT116 cells were transduced with lentiviral
vectors targeting Noxa (no. 1, no. 2, no. 3, and no. 2þno. 3), or with a vector targeting firefly luciferase (control). After selection in puromycin-containing
medium for 1 week, cells were lysed and analysed for Noxa protein levels by western blot analysis. (B) HCT116 control and Noxa knockdown (NoxaKD)
cells were treated with oxaliplatin (8mgml
 1) or 5-FU (8mgml
 1) for 0–3 days. The percentage of apoptotic cells was then determined by FACS analysis as
in Figure 1. Error bars represent s.e.m. of three independent experiments.
Figure 6 Contribution of Noxa to the therapeutic efficacy of oxaliplatin and 5-FU. (A) Immune-deficient nude mice (n¼8 per group) were injected
subcutaneously with 10
6 HCT116 control or HCT116-NoxaKD cells. When tumours reached a size of 100mm
3, the mice received either PBS or oxaliplatin
(12.5mgkg
 1) intraperitoneally (day 0). Seven days later, all mice received a second dose of either PBS or oxaliplatin. Tumour growth was followed by
caliper measurements every 2 days (*P¼0.048, **P¼0.008). (B) Tumours were harvested on day 7 and day 14. Of each group, two tumours (panels A, B)
were analysed for the presence of cleaved caspase-3 (as a marker for apoptosis) and for Noxa by western blotting. All tumours were analysed by
immunohistochemistry for Ki-67 (C) and cleaved caspase-3 (D) as markers for proliferation and apoptosis respectively. Ten random fields per tumour were
scored and the positive tumour areas were determined by automated computer analysis. The bar graphs represent the ratios of Ki-67 and caspase-3-positive
surface areas in oxaliplatin-treated xenografts vs control xenografts (*Po0.05). Representative images are shown on the right. Bars represent 50mm.
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streatment was initiated. Tumour growth in control mice was
unaffected by Noxa suppression (Figure 6A). Oxaliplatin treatment
strongly reduced the growth of control HCT116 tumours, but had
virtually no effect on Noxa-suppressed tumours (Figure 6A).
Tumours were then excised and analysed by western blotting and
immunohistochemistry, using Ki-67 and activated caspase-3 as
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smarkers for proliferation and apoptosis, respectively. Noxa
suppression was stable during the course of the experiment
(Figure 6B). Induction of caspase-3 processing by oxaliplatin was
completely abolished in Noxa-suppressed tumours (Figure 6B
and D). Oxaliplatin had a marginal but statistically significant
inhibitory effect on tumour cell proliferation, but this was not
affected by Noxa suppression (Figure 6C). These results show that
Noxa is a key determinant of the apoptotic, but not the cytostatic
response of HCT116 tumours to oxaliplatin chemotherapy.
DISCUSSION
In this study, we provide evidence that oncogenic KRAS facilitates
chemotherapy-induced apoptosis of HCT116 colorectal tumour
cells by cooperating with p53 in the induction of the pro-apoptotic
gene Noxa. p53-dependent induction of PUMA did not require
oncogenic KRAS. Both PUMA and Noxa belong to the class of
BH3-only proteins that function as neutralisers of the pro-survival
Bcl-2-like proteins (Willis and Adams, 2005). The contribution of
PUMA and Noxa to apoptosis induction varies considerably
between cell types (Shibue et al, 2003, 2006; Villunger et al, 2003;
Michalak et al, 2008). Apoptosis induction in colorectal cancer
cells by chemotherapy is partly (B50%) dependent on the
induction of PUMA (Wang et al, 2007). Noxa is expressed both
in the normal intestine and in most intestinal tumours (Jansson
et al, 2003), and Noxa deficiency strongly reduces p53-dependent
apoptosis in intestinal crypts following g-irradiation (Shibue et al,
2003). Our results show that Noxa also has an essential role in
chemotherapy-induced KRAS/p53-dependent apoptosis induction
in intestinal (colorectal) cancer cells. Taken together, optimal
p53-dependent apoptosis in colorectal cancer cells presumably
requires induction of both Noxa and PUMA to achieve maximal
neutralisation of Bcl-2 pro-survival proteins.
Importantly, p53 is not the only regulator of Noxa gene
expression. Transcription factors such as c-Myc, E2F1, and HIF1a
regulate Noxa expression in a p53-independent manner (Hershko
and Ginsberg, 2004; Hershko et al, 2005; Nikiforov et al, 2007;
Ploner et al, 2008). Interestingly, oncogenic KRAS is critical for
maintaining high c-Myc levels in the HCT116/Hkh2 system
(Shirasawa et al, 1993), and can promote expression of E2F1
(Berkovich and Ginsberg, 2001) and stabilisation of HIF1a
(Kikuchi et al, 2009). The stimulatory effect of oncogenic KRAS
on one or more of these transcription factors may explain why
basal Noxa levels are low in KRAS
D13-deleted tumour cells. p53 is
not required for maintaining basal levels of Noxa, but cooperates
with oncogenic KRAS to induce Noxa expression in response to
chemotherapy.
Expression of the H-Ras oncogene in primary cells causes
stabilisation of p53 by induction of the tumour suppressor p19
ARF
(p14
ARF in human cells) (Palmero et al, 1998). However, despite
the presence of a mutant KRAS allele in HCT116 cells, its p14
ARF
levels are relatively low (Javelaud and Besancon, 2002), and we did
not observe overt differences in basal or chemotherapy-induced
p53 stabilisation in cells with or without KRAS
D13. The control of
p53 signalling output by oncogenic KRAS may therefore involve
alterations in p53 post-translational modifications and/or binding
partners. Our study showed that deletion of KRAS
D13 strongly
reduced chemotherapy-induced phosphorylation of p53 at Ser37
and Ser392. Phosphorylation of both residues has been associated
with the transcriptional output of p53, although not with
apoptosis-specific gene regulation. As KRAS status did not affect
p53 stabilisation or p21 induction, KRAS
D13-controlled phosphor-
ylation of Ser37 and/or Ser392 may contribute to specifying p53
target gene induction. Interestingly, Ser37 phosphorylation
augments p53 acetylation by p300 (Sakaguchi et al, 1998) and
this promotes Noxa induction and apoptosis (Terui et al, 2003).
Phosphorylation of p53 at Ser46, Ser15, and Ser20 has also been
implicated in apoptosis-specific p53 signalling (Aylon and Oren,
2007). However, phosphorylation of these residues was either not
detected (Ser20, Ser46) or not regulated by KRAS status (Ser15) in
the HCT116 cell system.
Several additional determinants of the tumour cell response to
p53 activation have been identified. These include p53 post-
translational modifications, interaction partners, and proteins that
occupy p53 target gene promoters independently of p53 (Vousden
and Prives, 2009). Whether oncogenic KRAS alters any of these
additional pathways or whether differential phosphorylation at
Ser37 and/or Ser392 is sufficient to skew p53 signalling output
towards Noxa induction and apoptosis will be the subject of
further studies.
Oxaliplatin and 5-FU are the mainstay chemotherapeutics in the
treatment of patients with disseminated colorectal cancer. How-
ever, there are currently no reliable predictors for response to
chemotherapy (Allen et al, 2006; Longley et al, 2006; Walther et al,
2009). Meta-analyses of the literature on the impact of p53
abnormalities and KRAS mutations on therapy outcome showed
that neither p53 nor KRAS status had a predictive value (Munro
et al, 2005; Loriot et al, 2009). Our results suggest that tumours
expressing oncogenic KRAS in combination with wild-type p53
may respond best to chemotherapy. To the best of our knowledge,
this has so far not been addressed in large patient cohorts. Noxa
expression in a cohort of colorectal cancer patients treated with
5-FU was unrelated to treatment response (Sinicrope et al, 2008).
However, such negative correlations are hard to interpret, given
that Noxa induction in response to chemotherapy is transient.
Colorectal tumours express Noxa at normal levels (Jansson et al,
2003), and inactivating mutations have so far not been reported.
Therefore, the loss of Noxa function does not seem to be required
during colorectal tumour development. Indeed, the Noxa-depen-
dent apoptosis pathway is intact in colorectal tumour cells (Ravi
et al, 2004; Okumura et al, 2008). Furthermore, Noxa has been
identified as a tumour-specific inducer of breast carcinoma cell
death that spares non-transformed mammary cells (Suzuki et al,
2009). These observations suggest that the Noxa pathway may be
an attractive target for therapeutic exploitation.
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